Compare JLL & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JLL | DVA |
|---|---|---|
| Founded | 1997 | 1994 |
| Country | United States | United States |
| Employees | 48000 | N/A |
| Industry | Real Estate | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3B | 14.9B |
| IPO Year | 1997 | 2003 |
| Metric | JLL | DVA |
|---|---|---|
| Price | $336.84 | $183.09 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 4 |
| Target Price | ★ $365.33 | $156.75 |
| AVG Volume (30 Days) | 269.2K | ★ 524.9K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.13 | N/A |
| EPS | ★ 7.91 | 6.86 |
| Revenue | ★ $26,115,600,000.00 | $13,643,069,000.00 |
| Revenue This Year | $7.71 | $3.85 |
| Revenue Next Year | $6.99 | $3.07 |
| P/E Ratio | $43.53 | ★ $27.91 |
| Revenue Growth | ★ 11.45 | 6.46 |
| 52 Week Low | $259.83 | $101.00 |
| 52 Week High | $393.84 | $247.49 |
| Indicator | JLL | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 42.13 | 58.97 |
| Support Level | $334.29 | $191.57 |
| Resistance Level | $359.64 | $202.63 |
| Average True Range (ATR) | 10.19 | 4.35 |
| MACD | -3.58 | 3.19 |
| Stochastic Oscillator | 15.41 | 97.45 |
Jones Lang LaSalle is a global commercial real estate services and investment management company that helps clients buy, build, occupy, manage, and invest in property across office, industrial, retail, multifamily, hotel, and data center assets. For over 200 years, clients have trusted JLL, a Fortune 500 company, tracing its roots to firms including LaSalle Partners (founded in Chicago in 1968) and the centuries-old London firm Jones Lang Wootton, which merged in 1999 to form the modern JLL. Today the firm is a leading global commercial real estate services and investment management company with operations in over 80 countries, and a global workforce of more than 113,000, as of early 2026.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.